Cary P. Gross, MD

Articles by Cary P. Gross, MD

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

ByKevin W. Su, MD,Cary P. Gross, MD,Nicholas S. Downing, MD,Kerin B. Adelson, MD,Joseph S. Ross, MD, MHS

July 28th 2017

Evidentiary standards for new or supplementary cancer therapeutic indication approvals by the FDA are consistent with off-label indication inclusions on Medicare-referenced compendia.

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Latest Updated Articles

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
Published: February 12th 2016 | Updated:
Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion
Published: July 28th 2017 | Updated:

Cary P. Gross, MD

Articles by Cary P. Gross, MD

Cancer Therapeutic Clinical Trials Supporting FDA Approval and Compendia Inclusion

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution

Estradiol-Containing MHT May Impact Alzheimer Disease-Related Biomarkers in Postmenopausal Women

CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis

MHT Use Can Affect Cognitive Health Depending on Administration Method

What to Know About the Latest Pediatric Respiratory Infections